Abstract
Objective: Remission in schizophrenia patients is associated with neurocognitive, social, and role functioning during both the early and chronic stages of schizophrenia. It is well-established that the amplitudes of duration mismatch negativity (dMMN) and frequency MMN (fMMN) are reduced in schizophrenia patients. However, the potential link between MMN and remission has not been established. In this study, we investigated the relationship between MMNs and remission in first-episode schizophrenia (FES) and their association with neurocognitive and social functioning.Method: dMMN and fMMN were measured in 30 patients with FES and 22 healthy controls at baseline and after a mean of 3 years. Clinical symptoms and cognitive and social functioning in the patients were assessed at the time of MMN measurements by using the Positive and Negative Syndrome Scale (PANSS), modified Global Assessment of Functioning (mGAF), Schizophrenia Cognition Rating Scale (SCoRS), and the Brief Assessment of Cognition in Schizophrenia (BACS). Remission of the patients was defined using the criteria by the Remission in Schizophrenia Working Group; of the 30 patients with FES, 14 achieved remission and 16 did not.Results: Baseline dMMN amplitude was reduced in FES compared to healthy controls. Further, baseline dMMN in the non-remitters had decreased amplitude and prolonged latency compared to the remitters. MMN did not change during follow-up period regardless of parameters, diagnosis, or remission status. Baseline dMMN amplitude in FES was correlated with future SCoRS and PANSS total scores. Logistic regression analysis revealed that dMMN amplitude at baseline was a significant predictor of remission.Conclusions: Our findings suggest that dMMN amplitude may be a useful biomarker for predicting symptomatic remission and improvement of cognitive and social functions in FES.
Highlights
Symptom remission is thought to represent the principal target for psychopharmacological interventions in schizophrenia [1, 2], while the concept of clinical remission consists of improvements in cognitive and social functioning during the course of the illness [3]
Baseline duration mismatch negativity (dMMN) amplitude in first-episode schizophrenia (FES) was correlated with future Schizophrenia Cognition Rating Scale (SCoRS) and Positive and Negative Syndrome Scale (PANSS) total scores
Our findings suggest that dMMN amplitude may be a useful biomarker for predicting symptomatic remission and improvement of cognitive and social functions in FES
Summary
Symptom remission is thought to represent the principal target for psychopharmacological interventions in schizophrenia [1, 2], while the concept of clinical remission consists of improvements in cognitive and social functioning during the course of the illness [3]. Very few studies to date have attempted a detailed examination of a potential link between ERP at early stages after onset and clinical remission (i.e., symptom remission and improvements in cognitive and social functions) in schizophrenia. Further studies will be required to detect reliable biomarkers for predicting clinical and functional outcomes of schizophrenia, which may support treatment decisions based on the individual neurobiological differences
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
